Hematologic, Hepatic, Renal, and Lipid Laboratory Monitoring After Initiation of Combination Antiretroviral Therapy in the United States, 2000–2010
Year: 2013
Type: article
Study design: Observational Study
Abstract: We assessed laboratory monitoring after combination antiretroviral therapy initiation among 3678 patients in a large US multisite clinical cohort, censoring participants at last clinic visit, combination antiretroviral therapy change, or 3 years. Median days (interquartile range) to first hematologic, hepatic, renal, and lipid tests were 30 (18-53), 31 (19-56), 33 (20-59), and 350 (96-1106), respectively. At 1 year, approximately 80% received more than 2 hematologic, hepatic, and renal tests consistent with guidelines. However, only 40% received 1 or more lipid tests. Monitoring was more frequent in specific subgroups, likely reflecting better clinic attendance or clinician perception of higher susceptibility to toxicities.
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Northwestern University, Harvard University, University of Washington, Johns Hopkins University, Case Western Reserve University, National Institutes of Health, Agency for Healthcare Research and Quality, University of North Carolina at Chapel Hill, National Institute of Allergy and Infectious Diseases
Awards: G1531094742, G1798730344, G2127051194, COMPARATIVE SAFETY OF ANTIRETROVIRALS AMONG HIV-INFECTED PATIENTS: MINIMIZING COR, G6264465014, G654751394, G9000036922, G9000075494, G9000081321, Training in Sexually Transmitted Infections and HIV, North American AIDS Cohorts on Collaboration and Design (NAACCORD)
OpenAlex ID: W2069874637